R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Leveraging AI agents to eliminate ‘white space’ in clinical ...

Human-AI collaboration has the potential to mitigate gross productivity gaps and establish a new standard of clinical trial efficiency.

R&D

ESMO25: On partnerships between pharma and diagnostic develo...

Jane Li, Senior Director of Pharma CDx and CRO Partnership, Clinical Next Generation Sequencing Business, at Thermo Fisher Scientific discusses CDx.

R&D

Biotech’s biggest challenge isn’t scientific, but political ...

We speak to James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy & grandson of FDR

R&D

How lab automation reinforces regulatory compliance for bioa...

Automation holds the potential to enhance scientific rigour and operational efficiency while solving long-standing regulatory conundrums.

R&D

Changing Faces – Boards of Directors and Advisory Boards – A...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to report on.

R&D

Reimagining biopharma: How AI is reshaping discovery, develo...

No longer confined to experimental pilots, AI is becoming a catalyst for change across the entire biopharma value chain - but there are challenges.